Drug intelligence / Profile preview

bhv-7010

Development stage: Discontinued
Lead developer: Biohaven
Modality: Small Molecules
Administration: Unknown

Overview

BHV-7010 is an investigational drug developed by Biohaven for neurological diseases and psychotic disorders. It acts as a modulator of Kv7 (KCNQ) potassium channels, potentially influencing neuronal excitability linked to various neuropsychiatric and neurological conditions. The drug’s mechanism is classified as a Kv7 channel modulator, but according to available information, it has been discontinued after preclinical development. There are no detailed published data on specific disease indications, outcomes, or further mechanistic insights, and it has not progressed into late-phase clinical trials[7][4].

Other names: BHV-7010BHV7010BHV 7010

Targets

KCNQ2 (Potassium voltage-gated channel subfamily KQT member 2)

Beyond the preview

Go deeper on bhv-7010.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on bhv-7010.

Explore the full profile